Sandoz Scores Regional First With EU Launch Of Autoinjectable Stelara Rival

The Approved Autoinjector Presentation Puts Sandoz Ahead Of Competition

Doubling down on the launch of its Stelara biosimilar Pyzchiva in Europe last year, Sandoz has just released an autoinjectable version of the drug, with the aim to offer a more convenient option for ustekinumab patients.

(Shutterstock)

Sandoz has landed a regional first with its launch of the Stelara (ustekinumab) biosimilar Pyzchiva in autoinjector form in Europe, putting it one step ahead of other players.

While the company has already launched Pyzchiva in the EU last year in different presentations, the autoinjector could offer a...

More from Regulation

More from Generics Bulletin